Literature DB >> 25604313

Intensive Atorvastatin Therapy Attenuates the Inflammatory Responses in Monocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention via Peroxisome Proliferator-Activated Receptor γ Activation.

Jing Yang1, Changqing Liu, Linxia Zhang, Yanhui Liu, Aihua Guo, Huiwu Shi, Xiaoxia Liu, Ying Cheng.   

Abstract

Periprocedural myocardial injury is a prognostically important complication of percutaneous coronary intervention (PCI). However, it still remains unclear whether and how intensive atorvastatin therapy attenuates the unfavorable inflammatory responses of monocytes associated with PCI. The aim of the study was to investigate the impact of intensive atorvastatin therapy on inflammatory responses of monocytes in Chinese patients with unstable angina who received PCI in order to explore the potential anti-inflammatory mechanism. Ninety-six patients with unstable angina were randomly assigned to atorvastatin 80 mg (intensive) or atorvastatin 20 mg (conventional) treatment at a 1:1 ratio. Creatine kinase MB (CK-MB), cTnI, hs-CRP, and IL-6 were assessed, and circulating CD14(+) monocytes were simultaneously obtained using CD14 MicroBeads 2 h before and 24 h after PCI. Plasma levels of CK-MB, cTnI, hs-CRP, and IL-6 were higher in the conventional dose group versus those in the intensive dose group following PCI. Furthermore, intensive atorvastatin treatment markedly reduced the expressions and responses of Toll-like receptor 2 (TLR2), TLR4, and CCR2 of CD14(+) monocytes versus the conventional dose group and significantly increased the activated peroxisome-proliferator-activated receptor (PPAR) γ in the CD14(+) monocytes post-PCI. Notably, the changes in responses of TLR2, TLR4, and CCR2 of CD14(+) monocytes between the two groups were all reversed by PPARγ antagonist and augmented by PPARγ agonist. In conclusion, a single high (80 mg) loading dose of atorvastatin reduced the inflammatory response in Chinese patients with unstable angina following PCI. The anti-inflammatory role of intensive atorvastatin was possibly due to attenuation of inflammatory response in monocytes via PPARγ activation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25604313     DOI: 10.1007/s10753-015-0116-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  25 in total

1.  MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes.

Authors:  Norihiko Sakai; Takashi Wada; Kengo Furuichi; Kazuaki Shimizu; Satoshi Kokubo; Akinori Hara; Junya Yamahana; Toshiya Okumura; Kouji Matsushima; Hitoshi Yokoyama; Shuichi Kaneko
Journal:  J Leukoc Biol       Date:  2006-01-13       Impact factor: 4.962

Review 2.  Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction.

Authors:  Davena M Norris; Joe R Anderson
Journal:  Cardiol Rev       Date:  2012 Nov-Dec       Impact factor: 2.644

3.  Troponin criteria for myocardial infarction after percutaneous coronary intervention.

Authors:  Victor Novack; Michael Pencina; David J Cohen; Neal S Kleiman; Chen-Hsing Yen; Jorge F Saucedo; Peter B Berger; Donald E Cutlip
Journal:  Arch Intern Med       Date:  2012-02-27

4.  Inflammation, longevity, and cardiovascular diseases: role of polymorphisms of TLR4.

Authors:  Giuseppina Candore; Alessandra Aquino; Carmela Rita Balistreri; Matteo Bulati; Daniele Di Carlo; Maria Paola Grimaldi; Florinda Listì; Valentina Orlando; Sonya Vasto; Marco Caruso; Giuseppina Colonna-Romano; Domenico Lio; Calogero Caruso
Journal:  Ann N Y Acad Sci       Date:  2006-05       Impact factor: 5.691

Review 5.  PPAR agonists in the treatment of atherosclerosis.

Authors:  Gordon A Francis; Jean-Sébastien Annicotte; Johan Auwerx
Journal:  Curr Opin Pharmacol       Date:  2003-04       Impact factor: 5.547

6.  Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.

Authors:  T I Arefieva; T L Krasnikova; A V Potekhina; N U Ruleva; P I Nikitin; T I Ksenevich; B G Gorshkov; M V Sidorova; Zh D Bespalova; N B Kukhtina; S I Provatorov; E A Noeva; E I Chazov
Journal:  Inflamm Res       Date:  2011-07-10       Impact factor: 4.575

7.  Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy.

Authors:  Nikolaos G Frangogiannis; Oliver Dewald; Ying Xia; Guofeng Ren; Sandra Haudek; Thorsten Leucker; Daniela Kraemer; George Taffet; Barrett J Rollins; Mark L Entman
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

8.  Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.

Authors:  G Liuzzo; A Buffon; L M Biasucci; J R Gallimore; G Caligiuri; A Vitelli; S Altamura; G Ciliberto; A G Rebuzzi; F Crea; M B Pepys; A Maseri
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

Review 9.  Inflammation and restenosis after percutaneous coronary interventions.

Authors:  Konstantinos Toutouzas; Antonio Colombo; Christodoulos Stefanadis
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

Review 10.  Role of PPAR in cardiovascular diseases.

Authors:  Saibal Kumar Das; Ranjan Chakrabarti
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-06
View more
  8 in total

1.  Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach.

Authors:  Yujie Zhu; Yuxin Lin; Wenying Yan; Zhandong Sun; Zhi Jiang; Bairong Shen; Xiaoqian Jiang; Jingjing Shi
Journal:  Biomed Res Int       Date:  2016-12-01       Impact factor: 3.411

Review 2.  The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.

Authors:  Evangelos Diamantis; George Kyriakos; Lourdes Victoria Quiles-Sanchez; Paraskevi Farmaki; Theodoros Troupis
Journal:  Curr Cardiol Rev       Date:  2017

3.  Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.

Authors:  Jia-Nan Zou; Jing Xiao; Sha-Sha Hu; Chen-Sheng Fu; Xiao-Li Zhang; Zhen-Xing Zhang; Yi-Jun Lu; Wei-Jun Chen; Zhi-Bin Ye
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

Review 4.  Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion.

Authors:  Simón Quetzalcoatl Rodríguez-Lara; Ernesto German Cardona-Muñoz; Ernesto Javier Ramírez-Lizardo; Sylvia Elena Totsuka-Sutto; Araceli Castillo-Romero; Teresa Arcelia García-Cobián; Leonel García-Benavides
Journal:  Oxid Med Cell Longev       Date:  2016-12-28       Impact factor: 6.543

5.  Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.

Authors:  Allison B Reiss; Hirra A Arain; Lora J Kasselman; Heather A Renna; Juan Zhen; Iryna Voloshyna; Joshua DeLeon; Steven E Carsons; Michelle Petri
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

6.  Ginsenoside Rd Promotes Cardiac Repair After Myocardial Infarction by Modulating Monocytes/Macrophages Subsets Conversion.

Authors:  Tingyao Zhao; Xinting Wang; Qian Liu; Tianshu Yang; Huiyan Qu; Hua Zhou
Journal:  Drug Des Devel Ther       Date:  2022-08-22       Impact factor: 4.319

7.  Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases.

Authors:  Solima Sabeel; Bongani Motaung; Mumin Ozturk; Sandra Mukasa; Andre Pascal Kengne; Dirk Blom; Karen Sliwa; Emmanuel Nepolo; Gunar Günther; Robert J Wilkinson; Claudia Schacht; Friedrich Thienemann; Reto Guler
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

Review 8.  New Pharmacological Tools to Target Leukocyte Trafficking in Lung Disease.

Authors:  Kylie B R Belchamber; Michael J Hughes; Daniella A Spittle; Eloise M Walker; Elizabeth Sapey
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.